Business Context and Reporting Period
Company: BioNexus Gene Lab Corp. (BGLC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: BGLC operates through three primary segments: genomic screening services (MRNA Scientific), industrial chemical trading (Chemrex), and investment holding. The company is currently transitioning its chemical trading subsidiary toward a Contract Development and Manufacturing Organization (CDMO) model and is commercializing the VitaGuard™ minimal residual disease (MRD) platform in the ASEAN region following a strategic alliance with Fidelion Diagnostics.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $98,998 | $4,397,328 |
| Gross Profit | $12,192 | $711,515 |
| Gross Margin | 12.32% | 16.18% |
| Net Loss | $(830,026) | $(1,239,499) |
| Net Loss Per Share (Basic/Diluted) | $(0.343) | $(0.690) |
| Cash and Cash Equivalents | $2,391,945 | $1,537,189 |
| Total Assets | $8,726,423 | $9,252,784 |
| Total Liabilities | $947,981 | $637,856 |
| Working Capital | $4,130,471 | $4,927,781 |
| Accumulated Deficit | $(7,257,253) | $(6,427,227) |
Material Changes vs. Prior Period
- Revenue Collapse: Revenue decreased by 97.75% year-over-year (YoY) to $98,998. This was driven primarily by a 97.79% drop in the Chemrex segment due to lower business volume following management changes and legal disputes with former officers. MRNA Scientific revenue also declined 69.99% due to lower sales volume.
- Improved Loss Profile: Despite the revenue drop, the Net Loss improved by 33.04% to $(830,026). This was achieved through significant expense reductions, particularly in Sales and Marketing (down 92.28%) and General and Administrative expenses (down 31.09%).
- Provision for Credit Losses: The company recorded a provision for expected credit losses of $270,661, offset partially by a reversal of $118,126, reflecting ongoing collection efforts on Chemrex receivables.
- Liquidity: Cash and cash equivalents increased to $2.39 million, supported by proceeds from fixed deposit maturities and advances from directors, despite net cash used in operating activities of $570,162.
Guidance, Outlook, and Risks
- Strategic Initiatives:
- VitaGuard Commercialization: The company is in the deployment phase for the VitaGuard MRD platform in ASEAN. As of June 30, 2026, the platform has not yet generated revenue. Management is focused on regulatory, laboratory, and partner arrangements.
- Chemrex Transition: Management is exploring a transition to a CDMO business model to diversify beyond chemical trading.
- Digital Assets: The company maintains an Ethereum treasury strategy but held no digital assets as of June 30, 2026, while reviewing allocation strategies.
- Capital Resources: Management believes current cash and the $20 million "At-The-Market" (ATM) equity program with Maxim Group LLC are sufficient to fund operations for at least the next 12 months. As of the filing date, $267,311 had been raised under the ATM program.
- Risk Factors:
- Going Concern: The company has incurred an accumulated deficit of over $7.2 million and negative operating cash flows, raising substantial doubt about its ability to continue as a going concern without additional financing or improved operating results.
- Internal Controls: The company disclosed a material weakness in internal controls over financial reporting at the Chemrex subsidiary related to documentation and approval authority. Remediation is ongoing.
- Legal Proceedings: The company has issued Letters of Demand to five former Chemrex officers/directors for approximately $2.94 million in alleged unauthorized payments. No court proceedings have commenced as of the filing date.
Investor Verification Checklist
- Revenue Sustainability: Verify the timeline for VitaGuard revenue generation and the feasibility of the Chemrex CDMO transition given the current near-zero revenue base.
- Legal Recovery: Monitor the status of the $2.94 million claim against former Chemrex officers and the likelihood of recovery.
- Internal Control Remediation: Confirm the completion of the remediation plan for the material weakness in internal controls at the Chemrex subsidiary.
- Cash Burn Rate: Assess the sufficiency of the $2.39 million cash balance against the current operating loss rate and the potential need for further dilutive equity financing.
- Related Party Transactions: Review the $296,331 payable to Fidelion (related party) regarding the license agreement and the terms of the ARC Group International equity purchase facility.